NASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $33.63 -0.14 (-0.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$33.72 +0.09 (+0.28%) As of 08/1/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bright Minds Biosciences Stock (NASDAQ:DRUG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DRUG alerts:Sign Up Key Stats Today's Range$31.98▼$34.3750-Day Range$23.27▼$35.4652-Week Range$0.94▼$79.02Volume43,115 shsAverage Volume35,280 shsMarket Capitalization$236.89 millionP/E RatioN/ADividend YieldN/APrice Target$83.25Consensus RatingBuy Company Overview Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York. Read More Bright Minds Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreDRUG MarketRank™: Bright Minds Biosciences scored higher than 33% of companies evaluated by MarketBeat, and ranked 752nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingBright Minds Biosciences has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBright Minds Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Bright Minds Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($1.24) to ($3.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bright Minds Biosciences is -93.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bright Minds Biosciences is -93.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBright Minds Biosciences has a P/B Ratio of 36.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bright Minds Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.43% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Bright Minds Biosciences has recently increased by 2.61%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBright Minds Biosciences does not currently pay a dividend.Dividend GrowthBright Minds Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.43% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Bright Minds Biosciences has recently increased by 2.61%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 4 people have searched for DRUG on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bright Minds Biosciences' insider trading history. Receive DRUG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address DRUG Stock News HeadlinesBright Minds Biosciences Inc. (NASDAQ:DRUG) Receives $83.25 Consensus PT from BrokeragesJuly 24, 2025 | americanbankingnews.comBright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | finance.yahoo.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant. | The Oxford Club (Ad)Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025May 20, 2025 | globenewswire.comTD Cowen Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy RecommendationMay 14, 2025 | msn.comBright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101May 13, 2025 | finance.yahoo.comChardan Capital Initiates a Buy Rating on Bright Minds Biosciences (DRUG)May 9, 2025 | theglobeandmail.comEpilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock UpsideMay 7, 2025 | benzinga.comSee More Headlines DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed this year? Bright Minds Biosciences' stock was trading at $36.02 at the beginning of 2025. Since then, DRUG stock has decreased by 6.6% and is now trading at $33.63. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.10. When did Bright Minds Biosciences' stock split? Bright Minds Biosciences's stock reverse split on the morning of Friday, July 14th 2023.The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bright Minds Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include HubSpot (HUBS), Blink Charging (BLNK), ConocoPhillips (COP), Netflix (NFLX), ForgeRock (FORG) and SoFi Technologies (SOFI). Company Calendar Last Earnings5/15/2025Today8/01/2025Next Earnings (Estimated)8/13/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRUG CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Bright Minds Biosciences$83.25 High Price Target$93.00 Low Price Target$75.00 Potential Upside/Downside+147.5%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-14.56% Return on Assets-14.29% Debt Debt-to-Equity RatioN/A Current Ratio126.01 Quick Ratio126.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book36.55Miscellaneous Outstanding Shares7,044,000Free Float4,039,000Market Cap$236.89 million OptionableNot Optionable Beta-6.01 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:DRUG) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.